ABOzymes

ABOzymes Biomedical is a biotechnology company focused on transforming the blood transfusion and organ transplantation landscape by converting blood types. Utilizing a proprietary platform of enzymes discovered in the human gut microbiome, the company aims to remove A and B antigens from red blood cells and donor organs, effectively creating universal O-type blood and tissues. This technology addresses critical shortages in the global blood supply and reduces the risk of immunological rejection in transplants. The company is a spin-off from the University of British Columbia and is currently advancing its programs through the pre-clinical stage.